Outsourcers Who Most Heavily Rely On CDMOs Often Lack CDMO Selection Resources

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

One of the most surprising findings from recent ISR syndicated research is that 26% of drug innovators that outsource do not formally budget for the CDMO selection process. At first glance, this is not a meaningfully different proportion than ISR’s outsourcing models research showed in 2020, where 27% of respondents to the study reported their company does not formally budget for CDMO selection. However, when we dig deeper into the 2022 findings, the data show considerable differences by company size, differences that were not as pronounced just a couple of years ago.